MDGL vs VTR · rev $180.1M vs P/E 149, rev $5.83B
Madrigal Pharmaceuticals Inc (MDGL) versus Ventas Inc (VTR) — a side-by-side from cached financials, not a winner call.
Madrigal Pharmaceuticals Inc (MDGL) is a biotechnology company listed on NASDAQ.
Ventas Inc (VTR) is a reit - healthcare facilities company listed on NYSE.
Latest reported MDGL revenue for 2024-12-31 was $180.1M. Net income was -$465.9M. MDGL currently screens at market cap $11.56B.
Latest reported VTR revenue for 2025-12-31 was $5.83B. Net income was $261.5M. Revenue was up 18.5% from 2024-12-31 to 2025-12-31. VTR currently screens at market cap $39.94B and trailing P/E 149.4.
MDGL currently screens at market cap $11.56B. VTR currently screens at market cap $39.94B and trailing P/E 149.4.
Not investment advice. Open the MDGL and VTR stock pages for the full models.
Not investment advice.